生物制剂治疗hiv阳性患者的银屑病：文献综述

IF 3.7 4区医学 Q1 DERMATOLOGY

Dermatologic Therapy Pub Date : 2025-01-06 DOI:10.1155/dth/2370807

Miaoqi Qiu, Bo Feng, Chengyao Zhu, Lunfei Liu

{"title":"生物制剂治疗hiv阳性患者的银屑病：文献综述","authors":"Miaoqi Qiu, Bo Feng, Chengyao Zhu, Lunfei Liu","doi":"10.1155/dth/2370807","DOIUrl":null,"url":null,"abstract":"<div>\n <p>The management of HIV-positive psoriasis patients places a heavy burden on the healthcare system, as there are no standard treatment regimens for these patients and the use of biologics has only been reported sporadically. Here, we conducted a systematic review over the past six years and identified 22 articles containing 34 patients treated with inhibitors against tumor necrosis factor alpha (TNF-<i>α</i>), interleukin (IL)-12/23, IL-17, or IL-23. Our analysis focuses on the effectiveness and safety profile of biological agents, highlighting IL-23 inhibitor’s superior clinical response and tolerability for plaque psoriasis in concomitant HIV-positive patients. Therefore, we suggest IL-23 inhibitor as a promising treatment option for moderate-to-severe psoriasis in HIV-positive patients.</p>\n </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/2370807","citationCount":"0","resultStr":"{\"title\":\"Biological Agents for Psoriasis Management in HIV-Positive Patients: A Literature Review\",\"authors\":\"Miaoqi Qiu, Bo Feng, Chengyao Zhu, Lunfei Liu\",\"doi\":\"10.1155/dth/2370807\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n <p>The management of HIV-positive psoriasis patients places a heavy burden on the healthcare system, as there are no standard treatment regimens for these patients and the use of biologics has only been reported sporadically. Here, we conducted a systematic review over the past six years and identified 22 articles containing 34 patients treated with inhibitors against tumor necrosis factor alpha (TNF-<i>α</i>), interleukin (IL)-12/23, IL-17, or IL-23. Our analysis focuses on the effectiveness and safety profile of biological agents, highlighting IL-23 inhibitor’s superior clinical response and tolerability for plaque psoriasis in concomitant HIV-positive patients. Therefore, we suggest IL-23 inhibitor as a promising treatment option for moderate-to-severe psoriasis in HIV-positive patients.</p>\\n </div>\",\"PeriodicalId\":11045,\"journal\":{\"name\":\"Dermatologic Therapy\",\"volume\":\"2025 1\",\"pages\":\"\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2025-01-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/2370807\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dermatologic Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1155/dth/2370807\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatologic Therapy","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/dth/2370807","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

艾滋病毒阳性银屑病患者的管理给卫生保健系统带来了沉重的负担，因为没有针对这些患者的标准治疗方案，而且生物制剂的使用仅偶有报道。在这里，我们进行了一个系统的回顾，在过去的六年里，我们确定了22篇文章，其中包含34例使用肿瘤坏死因子α (TNF-α)、白细胞介素(IL)-12/23、IL-17或IL-23抑制剂治疗的患者。我们的分析侧重于生物制剂的有效性和安全性，强调IL-23抑制剂对伴发hiv阳性的斑块性银屑病患者具有卓越的临床反应和耐受性。因此，我们建议IL-23抑制剂作为hiv阳性患者中重度牛皮癣的一种有希望的治疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Biological Agents for Psoriasis Management in HIV-Positive Patients: A Literature Review

The management of HIV-positive psoriasis patients places a heavy burden on the healthcare system, as there are no standard treatment regimens for these patients and the use of biologics has only been reported sporadically. Here, we conducted a systematic review over the past six years and identified 22 articles containing 34 patients treated with inhibitors against tumor necrosis factor alpha (TNF-α), interleukin (IL)-12/23, IL-17, or IL-23. Our analysis focuses on the effectiveness and safety profile of biological agents, highlighting IL-23 inhibitor’s superior clinical response and tolerability for plaque psoriasis in concomitant HIV-positive patients. Therefore, we suggest IL-23 inhibitor as a promising treatment option for moderate-to-severe psoriasis in HIV-positive patients.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Dermatologic Therapy 医学-皮肤病学

CiteScore

7.00

自引率

8.30%

发文量

711

审稿时长

3 months

期刊介绍： Dermatologic Therapy has been created to fill an important void in the dermatologic literature: the lack of a readily available source of up-to-date information on the treatment of specific cutaneous diseases and the practical application of specific treatment modalities. Each issue of the journal consists of a series of scholarly review articles written by leaders in dermatology in which they describe, in very specific terms, how they treat particular cutaneous diseases and how they use specific therapeutic agents. The information contained in each issue is so practical and detailed that the reader should be able to directly apply various treatment approaches to daily clinical situations. Because of the specific and practical nature of this publication, Dermatologic Therapy not only serves as a readily available resource for the day-to-day treatment of patients, but also as an evolving therapeutic textbook for the treatment of dermatologic diseases.